APO RESEARCH · REPORT
Anti-tumor Drug
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
Product & engineering
Understand the product.
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
Selected research
Market Outlook & Growth Opportunities
Global Anti-tumor Drug Market Outlook and Growth Opportunities 2026
Market perspective
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
In China, Anti-tumor Drug key players include AstraZeneca, Merck & Co., Roche, Celgene, Johnson & Johnson, etc.
United States is the largest market, followed by Japan, and Europe.
Read the full market overview
This report provides an overview of the global Anti-tumor Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti-tumor Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-tumor Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anti-tumor Drug market.
Anti-tumor Drug Segment by Company
Roche
Novartis
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka
Anti-tumor Drug Segment by Type
Cytotoxic Drugs
Non-cytotoxic Drugs
Anti-tumor Drug Segment by Application
Alkylating Agents
Anti-Metabolism Drugs
Platinum Antineoplastic Agents
Anthracycline Antitumor Drugs
Microtubule Stabilizer
Endocrine Therapy Drugs
Immunotherapy Drugs
Gene Therapy Drugs
Targeted Antineoplastic Drugs
Anti-tumor Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Anti-tumor Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Anti-tumor Drug key companies, revenue, market share, and recent developments.
3. To split the Anti-tumor Drug breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Anti-tumor Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Anti-tumor Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Anti-tumor Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-tumor Drug industry.
Chapter 3: Detailed analysis of Anti-tumor Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Anti-tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Anti-tumor Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Anti-tumor Drug Industry Trends
Table 2. Anti-tumor Drug Industry Drivers
Table 3. Anti-tumor Drug Industry Opportunities and Challenges
Table 4. Anti-tumor Drug Industry Restraints
Table 5. Global Anti-tumor Drug Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Anti-tumor Drug Revenue Share by Company (2021-2026)
Table 7. Global Anti-tumor Drug Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Anti-tumor Drug Key Company Manufacturing Base & Headquarters
Table 9. Global Anti-tumor Drug Company, Product Type & Application
Table 10. Global Anti-tumor Drug Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Anti-tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Cytotoxic Drugs
Table 15. Significant Companies of Non-cytotoxic Drugs
Table 16. Global Anti-tumor Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 17. Global Anti-tumor Drug Sales Value by Type (2021-2026) & (US$ Million)
Table 18. Global Anti-tumor Drug Sales Value by Type (2027-2032) & (US$ Million)
Table 19. Global Anti-tumor Drug Sales Value Share by Type (2021-2026)
Table 20. Global Anti-tumor Drug Sales Value Share by Type (2027-2032)
Table 21. Significant Companies of Alkylating Agents
Table 22. Significant Companies of Anti-Metabolism Drugs
Table 23. Significant Companies of Platinum Antineoplastic Agents
Table 24. Significant Companies of Anthracycline Antitumor Drugs
Table 25. Significant Companies of Microtubule Stabilizer
Table 26. Significant Companies of Endocrine Therapy Drugs
Table 27. Significant Companies of Immunotherapy Drugs
Table 28. Significant Companies of Gene Therapy Drugs
Table 29. Significant Companies of Targeted Antineoplastic Drugs
Table 30. Global Anti-tumor Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 31. Global Anti-tumor Drug Sales Value by Application (2021-2026) & (US$ Million)
Table 32. Global Anti-tumor Drug Sales Value by Application (2027-2032) & (US$ Million)
Table 33. Global Anti-tumor Drug Sales Value Share by Application (2021-2026)
Table 34. Global Anti-tumor Drug Sales Value Share by Application (2027-2032)
Table 35. Global Anti-tumor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 36. Global Anti-tumor Drug Sales Value by Region (2021-2026) & (US$ Million)
Table 37. Global Anti-tumor Drug Sales Value Share by Region (2021-2026)
Table 38. Global Anti-tumor Drug Sales Value by Region (2027-2032) & (US$ Million)
Table 39. Global Anti-tumor Drug Sales Value Share by Region (2027-2032)
Table 40. Global Anti-tumor Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 41. Global Anti-tumor Drug Sales Value by Country (2021-2026) & (US$ Million)
Table 42. Global Anti-tumor Drug Sales Value Market Share by Country (2021-2026)
Table 43. Global Anti-tumor Drug Sales Value by Country (2027-2032) & (US$ Million)
Table 44. Global Anti-tumor Drug Sales Value Market Share by Country (2027-2032)
Table 45. Roche Company Information
Table 46. Roche Business Overview
Table 47. Roche Anti-tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 48. Roche Anti-tumor Drug Product Portfolio
Table 49. Roche Recent Development
Table 50. Novartis Company Information
Table 51. Novartis Business Overview
Table 52. Novartis Anti-tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Novartis Anti-tumor Drug Product Portfolio
Table 54. Novartis Recent Development
Table 55. Celgene Company Information
Table 56. Celgene Business Overview
Table 57. Celgene Anti-tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 58. Celgene Anti-tumor Drug Product Portfolio
Table 59. Celgene Recent Development
Table 60. Bristol-Myers Squibb Company Information
Table 61. Bristol-Myers Squibb Business Overview
Table 62. Bristol-Myers Squibb Anti-tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 63. Bristol-Myers Squibb Anti-tumor Drug Product Portfolio
Table 64. Bristol-Myers Squibb Recent Development
Table 65. Amgen Company Information
Table 66. Amgen Business Overview
Table 67. Amgen Anti-tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 68. Amgen Anti-tumor Drug Product Portfolio
Table 69. Amgen Recent Development
Table 70. Johnson & Johnson Company Information
Table 71. Johnson & Johnson Business Overview
Table 72. Johnson & Johnson Anti-tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 73. Johnson & Johnson Anti-tumor Drug Product Portfolio
Table 74. Johnson & Johnson Recent Development
Table 75. Pfizer Company Information
Table 76. Pfizer Business Overview
Table 77. Pfizer Anti-tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 78. Pfizer Anti-tumor Drug Product Portfolio
Table 79. Pfizer Recent Development
Table 80. Takeda Company Information
Table 81. Takeda Business Overview
Table 82. Takeda Anti-tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 83. Takeda Anti-tumor Drug Product Portfolio
Table 84. Takeda Recent Development
Table 85. Eli Lilly Company Information
Table 86. Eli Lilly Business Overview
Table 87. Eli Lilly Anti-tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 88. Eli Lilly Anti-tumor Drug Product Portfolio
Table 89. Eli Lilly Recent Development
Table 90. AstraZeneca Company Information
Table 91. AstraZeneca Business Overview
Table 92. AstraZeneca Anti-tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 93. AstraZeneca Anti-tumor Drug Product Portfolio
Table 94. AstraZeneca Recent Development
Table 95. Astellas Company Information
Table 96. Astellas Business Overview
Table 97. Astellas Anti-tumor Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 98. Astellas Anti-tumor Drug Product Portfolio
Table 99. Astellas Recent Development
Table 100. Merck & Co Company Information
Table 101. Merck & Co Business Overview
Table 102. Merck & Co Anti-tumor Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 103. Merck & Co Anti-tumor Drug Product Portfolio
Table 104. Merck & Co Recent Development
Table 105. Sanofi Company Information
Table 106. Sanofi Business Overview
Table 107. Sanofi Anti-tumor Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 108. Sanofi Anti-tumor Drug Product Portfolio
Table 109. Sanofi Recent Development
Table 110. Bayer Company Information
Table 111. Bayer Business Overview
Table 112. Bayer Anti-tumor Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 113. Bayer Anti-tumor Drug Product Portfolio
Table 114. Bayer Recent Development
Table 115. Biogen Idec Company Information
Table 116. Biogen Idec Business Overview
Table 117. Biogen Idec Anti-tumor Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 118. Biogen Idec Anti-tumor Drug Product Portfolio
Table 119. Biogen Idec Recent Development
Table 120. Eisai Company Information
Table 121. Eisai Business Overview
Table 122. Eisai Anti-tumor Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 123. Eisai Anti-tumor Drug Product Portfolio
Table 124. Eisai Recent Development
Table 125. Teva Company Information
Table 126. Teva Business Overview
Table 127. Teva Anti-tumor Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 128. Teva Anti-tumor Drug Product Portfolio
Table 129. Teva Recent Development
Table 130. Otsuka Company Information
Table 131. Otsuka Business Overview
Table 132. Otsuka Anti-tumor Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026)
Table 133. Otsuka Anti-tumor Drug Product Portfolio
Table 134. Otsuka Recent Development
Table 135. Research Programs/Design for This Report
Table 136. Authors List of This Report
Table 137. Secondary Sources
Table 138. Primary Sources
List of Figures
Figure 1. Anti-tumor Drug Product Image
Figure 2. Global Anti-tumor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Anti-tumor Drug Market Size (2021-2032) & (US$ Million)
Figure 4. Global Anti-tumor Drug Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Cytotoxic Drugs Image
Figure 8. Non-cytotoxic Drugs Image
Figure 9. Global Anti-tumor Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global Anti-tumor Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 11. Global Anti-tumor Drug Sales Value Share by Type (2021-2032)
Figure 12. Alkylating Agents Image
Figure 13. Anti-Metabolism Drugs Image
Figure 14. Platinum Antineoplastic Agents Image
Figure 15. Anthracycline Antitumor Drugs Image
Figure 16. Microtubule Stabilizer Image
Figure 17. Endocrine Therapy Drugs Image
Figure 18. Immunotherapy Drugs Image
Figure 19. Gene Therapy Drugs Image
Figure 20. Targeted Antineoplastic Drugs Image
Figure 21. Global Anti-tumor Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 22. Global Anti-tumor Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 23. Global Anti-tumor Drug Sales Value Share by Application (2021-2032)
Figure 24. Global Anti-tumor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 25. Global Anti-tumor Drug Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 26. North America Anti-tumor Drug Sales Value (2021-2032) & (US$ Million)
Figure 27. North America Anti-tumor Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 28. Europe Anti-tumor Drug Sales Value (2021-2032) & (US$ Million)
Figure 29. Europe Anti-tumor Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 30. Asia-Pacific Anti-tumor Drug Sales Value (2021-2032) & (US$ Million)
Figure 31. Asia-Pacific Anti-tumor Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 32. South America Anti-tumor Drug Sales Value (2021-2032) & (US$ Million)
Figure 33. South America Anti-tumor Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 34. Middle East & Africa Anti-tumor Drug Sales Value (2021-2032) & (US$ Million)
Figure 35. Middle East & Africa Anti-tumor Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 36. USA Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 37. USA Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 38. USA Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 39. Canada Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 40. Canada Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 41. Canada Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 42. Mexico Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 43. Mexico Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 44. Mexico Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 45. Germany Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 46. Germany Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 47. Germany Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 48. France Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 49. France Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 50. France Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 51. U.K. Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 52. U.K. Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 53. U.K. Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 54. Italy Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 55. Italy Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 56. Italy Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 57. Spain Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 58. Spain Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 59. Spain Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 60. Russia Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 61. Russia Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 62. Russia Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 63. Netherlands Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 64. Netherlands Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 65. Netherlands Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 66. Nordic Countries Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 67. Nordic Countries Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 68. Nordic Countries Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 69. China Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 70. China Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 71. China Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 72. Japan Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 73. Japan Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 74. Japan Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 75. South Korea Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 76. South Korea Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 77. South Korea Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 78. India Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 79. India Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 80. India Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 81. Australia Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 82. Australia Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 83. Australia Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 84. Southeast Asia Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 85. Southeast Asia Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 86. Southeast Asia Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 87. Brazil Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 88. Brazil Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 89. Brazil Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 90. Argentina Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 91. Argentina Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 92. Argentina Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 93. Chile Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 94. Chile Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 95. Chile Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 96. Colombia Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 97. Colombia Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 98. Colombia Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 99. Peru Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 100. Peru Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 101. Peru Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 102. Saudi Arabia Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 103. Saudi Arabia Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 104. Saudi Arabia Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 105. Israel Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 106. Israel Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 107. Israel Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 108. UAE Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 109. UAE Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 110. UAE Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 111. Turkey Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 112. Turkey Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 113. Turkey Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 114. Iran Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 115. Iran Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 116. Iran Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 117. Egypt Anti-tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 118. Egypt Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 119. Egypt Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 120. Years Considered
Figure 121. Research Process
Figure 122. Key Executives Interviewed
Scope & coverage.
Types
- Cytotoxic Drugs
- Non-cytotoxic Drugs
Applications
- Alkylating Agents
- Anti-Metabolism Drugs
- Platinum Antineoplastic Agents
- Anthracycline Antitumor Drugs
- Microtubule Stabilizer
- Endocrine Therapy Drugs
- Immunotherapy Drugs
- Gene Therapy Drugs
- Targeted Antineoplastic Drugs
Companies covered
- Roche
- Novartis
- Celgene
- Bristol-Myers Squibb
- Amgen
- Johnson & Johnson
- Pfizer
- Takeda
- Eli Lilly
- AstraZeneca
- Astellas
- Merck & Co
- Sanofi
- Bayer
- Biogen Idec
- Eisai
- Teva
- Otsuka
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Anti-tumor Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Anti-tumor Drug Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Anti-tumor Drug Market Dynamics
- 2.1 Anti-tumor Drug Industry Trends
- 2.2 Anti-tumor Drug Industry Drivers
- 2.3 Anti-tumor Drug Industry Opportunities and Challenges
- 2.4 Anti-tumor Drug Industry Restraints
3 Anti-tumor Drug Market by Company
- 3.1 Global Anti-tumor Drug Company Revenue Ranking in 2025
- 3.2 Global Anti-tumor Drug Revenue by Company (2021-2026)
- 3.3 Global Anti-tumor Drug Company Ranking (2024-2026)
- 3.4 Global Anti-tumor Drug Company Manufacturing Base and Headquarters
- 3.5 Global Anti-tumor Drug Company Product Type and Application
- 3.6 Global Anti-tumor Drug Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Anti-tumor Drug Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Anti-tumor Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Anti-tumor Drug Market by Type
- 4.1 Anti-tumor Drug Type Introduction
- 4.1.1 Cytotoxic Drugs
- 4.1.2 Non-cytotoxic Drugs
- 4.2 Global Anti-tumor Drug Sales Value by Type
- 4.2.1 Global Anti-tumor Drug Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Anti-tumor Drug Sales Value by Type (2021-2032)
- 4.2.3 Global Anti-tumor Drug Sales Value Share by Type (2021-2032)
5 Anti-tumor Drug Market by Application
- 5.1 Anti-tumor Drug Application Introduction
- 5.1.1 Alkylating Agents
- 5.1.2 Anti-Metabolism Drugs
- 5.1.3 Platinum Antineoplastic Agents
- 5.1.4 Anthracycline Antitumor Drugs
- 5.1.5 Microtubule Stabilizer
- 5.1.6 Endocrine Therapy Drugs
- 5.1.7 Immunotherapy Drugs
- 5.1.8 Gene Therapy Drugs
- 5.1.9 Targeted Antineoplastic Drugs
- 5.2 Global Anti-tumor Drug Sales Value by Application
- 5.2.1 Global Anti-tumor Drug Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Anti-tumor Drug Sales Value by Application (2021-2032)
- 5.2.3 Global Anti-tumor Drug Sales Value Share by Application (2021-2032)
6 Anti-tumor Drug Regional Value Analysis
- 6.1 Global Anti-tumor Drug Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Anti-tumor Drug Sales Value by Region (2021-2032)
- 6.2.1 Global Anti-tumor Drug Sales Value by Region: 2021-2026
- 6.2.2 Global Anti-tumor Drug Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Anti-tumor Drug Sales Value (2021-2032)
- 6.3.2 North America Anti-tumor Drug Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Anti-tumor Drug Sales Value (2021-2032)
- 6.4.2 Europe Anti-tumor Drug Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Anti-tumor Drug Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Anti-tumor Drug Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Anti-tumor Drug Sales Value (2021-2032)
- 6.6.2 South America Anti-tumor Drug Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Anti-tumor Drug Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Anti-tumor Drug Sales Value Share by Country, 2025 VS 2032
7 Anti-tumor Drug Country-level Value Analysis
- 7.1 Global Anti-tumor Drug Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Anti-tumor Drug Sales Value by Country (2021-2032)
- 7.2.1 Global Anti-tumor Drug Sales Value by Country (2021-2026)
- 7.2.2 Global Anti-tumor Drug Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.7.2 France Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.14.2 China Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.17.2 India Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Anti-tumor Drug Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Anti-tumor Drug Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Anti-tumor Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Roche
- 8.1.1 Roche Company Information
- 8.1.2 Roche Business Overview
- 8.1.3 Roche Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.1.4 Roche Anti-tumor Drug Product Portfolio
- 8.1.5 Roche Recent Developments
- 8.2 Novartis
- 8.2.1 Novartis Company Information
- 8.2.2 Novartis Business Overview
- 8.2.3 Novartis Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.2.4 Novartis Anti-tumor Drug Product Portfolio
- 8.2.5 Novartis Recent Developments
- 8.3 Celgene
- 8.3.1 Celgene Company Information
- 8.3.2 Celgene Business Overview
- 8.3.3 Celgene Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.3.4 Celgene Anti-tumor Drug Product Portfolio
- 8.3.5 Celgene Recent Developments
- 8.4 Bristol-Myers Squibb
- 8.4.1 Bristol-Myers Squibb Company Information
- 8.4.2 Bristol-Myers Squibb Business Overview
- 8.4.3 Bristol-Myers Squibb Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.4.4 Bristol-Myers Squibb Anti-tumor Drug Product Portfolio
- 8.4.5 Bristol-Myers Squibb Recent Developments
- 8.5 Amgen
- 8.5.1 Amgen Company Information
- 8.5.2 Amgen Business Overview
- 8.5.3 Amgen Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.5.4 Amgen Anti-tumor Drug Product Portfolio
- 8.5.5 Amgen Recent Developments
- 8.6 Johnson & Johnson
- 8.6.1 Johnson & Johnson Company Information
- 8.6.2 Johnson & Johnson Business Overview
- 8.6.3 Johnson & Johnson Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.6.4 Johnson & Johnson Anti-tumor Drug Product Portfolio
- 8.6.5 Johnson & Johnson Recent Developments
- 8.7 Pfizer
- 8.7.1 Pfizer Company Information
- 8.7.2 Pfizer Business Overview
- 8.7.3 Pfizer Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.7.4 Pfizer Anti-tumor Drug Product Portfolio
- 8.7.5 Pfizer Recent Developments
- 8.8 Takeda
- 8.8.1 Takeda Company Information
- 8.8.2 Takeda Business Overview
- 8.8.3 Takeda Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.8.4 Takeda Anti-tumor Drug Product Portfolio
- 8.8.5 Takeda Recent Developments
- 8.9 Eli Lilly
- 8.9.1 Eli Lilly Company Information
- 8.9.2 Eli Lilly Business Overview
- 8.9.3 Eli Lilly Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.9.4 Eli Lilly Anti-tumor Drug Product Portfolio
- 8.9.5 Eli Lilly Recent Developments
- 8.10 AstraZeneca
- 8.10.1 AstraZeneca Company Information
- 8.10.2 AstraZeneca Business Overview
- 8.10.3 AstraZeneca Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.10.4 AstraZeneca Anti-tumor Drug Product Portfolio
- 8.10.5 AstraZeneca Recent Developments
- 8.11 Astellas
- 8.11.1 Astellas Company Information
- 8.11.2 Astellas Business Overview
- 8.11.3 Astellas Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.11.4 Astellas Anti-tumor Drug Product Portfolio
- 8.11.5 Astellas Recent Developments
- 8.12 Merck & Co
- 8.12.1 Merck & Co Company Information
- 8.12.2 Merck & Co Business Overview
- 8.12.3 Merck & Co Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.12.4 Merck & Co Anti-tumor Drug Product Portfolio
- 8.12.5 Merck & Co Recent Developments
- 8.13 Sanofi
- 8.13.1 Sanofi Company Information
- 8.13.2 Sanofi Business Overview
- 8.13.3 Sanofi Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.13.4 Sanofi Anti-tumor Drug Product Portfolio
- 8.13.5 Sanofi Recent Developments
- 8.14 Bayer
- 8.14.1 Bayer Company Information
- 8.14.2 Bayer Business Overview
- 8.14.3 Bayer Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.14.4 Bayer Anti-tumor Drug Product Portfolio
- 8.14.5 Bayer Recent Developments
- 8.15 Biogen Idec
- 8.15.1 Biogen Idec Company Information
- 8.15.2 Biogen Idec Business Overview
- 8.15.3 Biogen Idec Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.15.4 Biogen Idec Anti-tumor Drug Product Portfolio
- 8.15.5 Biogen Idec Recent Developments
- 8.16 Eisai
- 8.16.1 Eisai Company Information
- 8.16.2 Eisai Business Overview
- 8.16.3 Eisai Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.16.4 Eisai Anti-tumor Drug Product Portfolio
- 8.16.5 Eisai Recent Developments
- 8.17 Teva
- 8.17.1 Teva Company Information
- 8.17.2 Teva Business Overview
- 8.17.3 Teva Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.17.4 Teva Anti-tumor Drug Product Portfolio
- 8.17.5 Teva Recent Developments
- 8.18 Otsuka
- 8.18.1 Otsuka Company Information
- 8.18.2 Otsuka Business Overview
- 8.18.3 Otsuka Anti-tumor Drug Revenue and Gross Margin (2021-2026)
- 8.18.4 Otsuka Anti-tumor Drug Product Portfolio
- 8.18.5 Otsuka Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst